Carolina Salvi

Learn More
The impact of dizziness on Quality of Life (QoL) can be assessed by the Dizziness Handicap Inventory (DHI), which is used as a discriminative and evaluative tool. Although the DHI is available in several languages, an equivalent version for the Italian population is not yet available. Aim of this study was to translate the DHI into the Italian language(More)
A long-term-cultured cytotoxic T lymphocyte (CTL) line (E/88) was obtained from splenic lymphocytes of BALB/c (H-2 d) mice bearing the weakly immunogenic colonic carcinoma C26. This line was shown to be α/βTCR+Vβ6+CD3+CD8+CD4− and to recognize a common tumour-associated antigen on syngeneic carcinomas and sarcomas in a(More)
We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that(More)
In-vitro-generated lymphokine-activated killer (LAK) cells of BALB/c mice, bearing the syngeneic colon carcinoma C-26 for 7 days, were as efficient as those from normal mice in lysing C-26 cells whereas LAK cells from 14-day tumor-bearing and 5- and 14-day tumor-resected animals had a lower C-26 cytotoxicity. The level of C-26 lysis returned to normal(More)
We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (approximately 80%) of the(More)
This article reports the results of adjuvant immunotherapy studies carried out in an experimental tumor model system. A transplantable murine BALB/c colonic adenocarcinoma (C-26) was used to evaluate the therapeutic potential of treatment with recombinant interleukin 2 (rIL-2) at high and low dosage in combination with or without lymphokine activated killer(More)
In order to determine whether lymphocytes with therapeutic potential can be obtained from colon carcinoma (C26)-bearing (TB) mice, splenocytes were activated either in mixed lymphocyte-tumor cell (MLTC) cultures in the presence of 5 and 10 U/ml IL2 or 250 and 100 U/ml IL2 (LAK effectors). The therapeutic efficacy, as well as functional and phenotypic(More)
s 3 tumors and lymphomas. Under these conditions most animals develop measurable growing tumors by day 7 and show multiple lung and lymph node metastases when autopsied on day 21. However, the production of metastases depends on the number of cells injected and on the ATS dose used. Using melanoma cell lines, we showed that this model is highly sensitive,(More)
  • 1